Prostate Cancer

“I think as technology evolves, we as urologists need to continue to evolve and make changes to our practice,” says Kevin T. Keating, DO.

The PARP inhibitors olaparib and rucaparib are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer.

"Our success depends on your assertive action and membership in organizations serving our specialty—the AACU in particular—as well as your state medical association," writes William C. Reha, MD, MBA.

Wassim Abida, MD, PhD, discusses whether he would recommend PARP inhibitors in patients with metastatic castration-resistant prostate cancer harboring alterations in homologous recombination repair genes other than BRCA1/2.

“While many patients may think of imaging tests, as many other tests, as [having] a binary outcome, it may be important to have a discussion about how the scoring and MRI works, [and] what the patient can expect to see on their report,” says Stella K. Kang, MD.

Decipher Prostate Biopsy, a 22-gene microarray-based genomic classifier, showed potential as a tool to help guide decisions between active surveillance and radical treatment in men with localized prostate cancer.

“What I found exciting was that the extent to which a…PI-RADS 4 score saved biopsies without really affecting the likelihood of detecting clinically significant tumor,” says Stella K. Kang, MD.

Researchers from the FDA’s Center for Drug Evaluation and Research determined that the benefits of androgen receptor inhibitors outweighed the risks in men aged ≥80 years with nonmetastatic castration-resistant prostate cancer.

Adjuvant radiotherapy (RT) after radical prostatectomy was associated with a reduced risk of all-cause mortality compared with early salvage RT.

Vinayak G. Wagaskar, MBBS, shares potential explanations for the obesity paradox in patients with metastatic castration-resistant prostate cancer and provides next steps for exploring this phenomenon.

“There's a lot that urologists can pick up on how to better interact with their patients,” says David King Keller, PhD, of Active Surveillance Patients International.

Evangelia Sereti, MSc, PhD, discusses the design/methodology and results of a preclinical study exploring the combination of the PARP inhibitor olaparib plus the novel agent NOV202 in BRCA1/2-mutated prostate cancer cells.

This article features insights from David Albala, MD, and Judd W. Moul, MD, on using liquid biomarker-based testing for the early detection of prostate cancer.

Vinayak G. Wagaskar, MBBS, explains the “obesity paradox”—improved survival outcomes in patients with a high body mass index—that has been observed in patients with genitourinary malignancies, including prostate cancer.

Prostate cancer screening with MRI-guided biopsy reduced the detection of clinically insignificant prostate cancer versus use of standard biopsy alone, while also demonstrating noninferiority for detecting clinically significant disease.

Screening rates rebounded across most tumor types in late 2020; however, racial and economic disparities persisted.

The so-called “obesity paradox” previously reported in other genitourinary malignancies has now been observed in patients with metastatic castration-resistant prostate cancer.

Between 40% and 50% of patients with mCRPC have loss in PTEN, which is associated with worse prognosis and reduced benefit from AR blockade.

In this subgroup, adjuvant radiotherapy significantly reduced the risk of all-cause mortality versus early salvage radiation therapy.

Expert urologists remark on unmet needs in prostate cancer by emphasizing the importance of reaching under-served communities, addressing patient discomfort, increasing education about liquid biopsy testing, and standardizing prostate size assessment.

“With 18F-DCFPyL-PET/CT, we can find metastatic disease much sooner. Therefore, 1 question that will need to be addressed is: what do we do now?” says Kenneth J. Pienta, MD.

Health care providers focus on genomic testing in heavily treated, metastatic castrate-resistant prostate cancer from the multidisciplinary approach to cancer care.

Health care providers focus on genomic testing in newly diagnosed, high grade, high-risk prostate cancer from the multidisciplinary approach to cancer care.

The approval is based on a subgroup analysis of the pivotal phase 3 PROfound trial.

Key opinion leaders in urology review factors to consider when selecting screening and risk-assessment tests for the diagnosis of prostate cancer including insurance coverage, commercial availability, and patient preference.

David Albala, MD and Judd W. Moul, MD consider the impact that COVID-19 has had on the clinical experience of patients with prostate cancer and share personal insights regarding telehealth and patient compliance.

The study is enrolling patients with DNA damage response–deficient metastatic castration-sensitive disease.

"As someone once told me, if you make a change in your golf swing and it is easy, more than likely you have not changed anything," writes Raoul S. Concepcion, MD, FACS.

Two experts in the management of prostate cancer provide key insight into the value of blood and urine liquid biopsy tests when deciding whether to perform a prostate tissue biopsy.

Thought leaders in the management of prostate cancer build a discussion on the challenges associated with the use of MRI to diagnose prostate cancer including insurance coverage and patient discomfort.